🇺🇸 FDA
Pipeline program

OTL-103, OTL-103

WAS-TLT003-01

Phase 3 small_molecule active

Quick answer

OTL-103, OTL-103 for Wiskott-Aldrich syndrome (WAS) is a Phase 3 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

Program details

Company
Fondazione Telethon ETS
Indication
Wiskott-Aldrich syndrome (WAS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials